Cyclotron and Radiochemistry Specialized Resource

回旋加速器和放射化学专业资源

基本信息

批准号：
8330933
负责人：
NAGICHETTIAR SATYAMURTHY
金额：
$ 7.51万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8330933
关键词：
Acetates Adenovirus Vector Adenoviruses Adopted Adoptive Cell Transfers Affinity Animal Model Animals Applications Grants Automobile Driving Back Basic Science Binding Biological Biological Markers Biology Cancer Biology Cell Proliferation Cell physiology Cells Cellular biology Choline Clinical Collaborations Colorectal Cancer Communities Complement Core Facility Coxibs Cyclotrons Cytosine Deltastab Deoxycytidine Kinase Department of Energy Development Diagnostic Discipline of Nuclear Medicine Earthquakes Enzymes Fatty Acids Fluorides Fostering Funding Gene Expression Genes Glioblastoma Grant Growth Herpesvirus 1 High Pressure Liquid Chromatography Housing Human Image Imaging Device Imaging Techniques Immune Immunocompetent Immunodeficient Mouse Income Individual Inhibitory Concentration 50 Injection of therapeutic agent Institutes Ions Label Laboratories Lesion Lipids Liver Lymphocyte Maintenance Malignant - descriptor Malignant Neoplasms Measures Medical Medical center Medicine Metabolism Modeling Molecular Molecular Biology Molecular Medicine Monitor Mus Nature Nuclear Energy Nuclear Reactors Nucleosides Oncogenic Pathway interactions Patients Peripheral Nerves Plant Roots Play Positron Positron-Emission Tomography Preparation Principal Investigator Procedures Process Production Protons Radioactive Radiochemistry Radioisotopes Radiolabeled Reagent Recording of previous events Reporter Genes Research Research Personnel Research Project Grants Research Support Resource Sharing Resources Retroviral Vector Rewards Role Series Services Signal Transduction Simplexvirus Sirolimus T-Cell Receptor Techniques Therapeutic Thymidine Kinase Time Tracer Transgenic Organisms Tumor Burden United States Virus Work Xenograft Model Xenograft procedure analog base cancer cell chemical property cyclooxygenase 2 gain of function genetic manipulation glucose metabolism imaging probe immune activation in vivo in vivo Cellular and Molecular Imaging Centers instrumentation lipid metabolism meetings molecular imaging mouse model novel nucleoside analog operation oxidation physical property preclinical study programs promoter radiochemical radiotracer repaired research study response sarcoma small molecule soft tissue suicide gene thymidine kinase 1 tool transgene expression tumor tumor growth tumor xenograft vector

项目摘要

Specialized Resource 1 Principal investigator/Program Director (Last, First, Middle): Herschman, Harvey R. D.1. CYCLOTRON AND RADIOCHEMISTRY SPECIALIZED RESOURCE {DIRECTOR, N. SATYAMURTHY. PH.D.) D.1.1. Introduction. The Cyclotron and Radiochemistry facility is a Specialized Resource component of both the UCLA-ICMIC and the UCLA Institute of Molecular Medicine (IMED) program. IMED had it roots in the longstanding Department of Energy-supported effort in positron emission tomography research at UCLA. Our history with the IMED program thus predates the initiation of the NCI ICMIC, extending back for over nearly four decades, when it was associated with the Atomic Energy Commission, and later the Department of Energy. The prime objective of the Cyclotron and Radiochemistry Specialized Resource of the UCLA ICMIC is to support both research and production for all positron-emitting probe needs of UCLA-ICMIC investigators, and to serve other UCLA research projects that complement these research programs. The UCLA Cyclotron and Radiochemistry Specialized Resource began its operation in July 1971. During the 1960s the Division of Biology and Medicine of the US Atomic Energy Commission (AEC, the predecessor of Department of Energy) undertook a program of fostering the installation and operation of compact cyclotrons at several medical centers across the United States. The intent was to stimulate the development of radioactive nuclides as diagnostic tools in medicine by making available a large number of promising radionuclides with desirable physical and chemical properties, but which could not be produced in nuclear reactors. As a consequence, an AEC-sponsored medical cyclotron program was initiated at UCLA and a model CS-22 cyclotron built by the Cyclotron Corporation (Berkeley, CA) capable of accelerating H*, D'', ^He** and ''He^'^ at fixed energies of 22, 12, 31, and 24 MeV, respectively was installed in a specially built vault at UCLA in 1971. A radiochemistry laboratory and a machine shop along with the cyclotron, all housed in a single story building adjacent to the UCLA Medical Center, formed the original cyclotron core laboratory. Due to increasing demand for radioisotopes, in 1990 a new 11 MeV proton RDS-112 negative ion cyclotron (manufactured by CTI, Knoxville TN) in a new building next to the CS-22 cyclotron building was added to the Radiochemistry Specialized Resource. The consequences of the Northridge earthquake of January 1994 mandated a replacement of the CS-22 cyclotron. An 11 MeV proton only RDS-112 negative ion cyclotron (manufactured by CTI Knoxville, TN) replaced the damaged CS-22 accelerator in June 1994. A complete renovation of the cyclotron laboratory took place in 1997, for the first time since the inception of the facility. The new compact, self-shielded RDS-112 cyclotron occupies only one half of the vault that the CS-22 cyclotron previously occupied, allowing the other half to be used for maintenance and repair of cyclotron-related components. The Cyclotron and Radiochemistry Specialized Resource, since its inception in 1971, has an excellent history of supporting the needs of UCLA Nuclear Medicine research. With the CS-22 cyclotron, this Specialized Resource has developed or adopted techniques for the production of more than twenty five different radioisotopes. As a centralized service unit, the Cyclotron and Radiochemistry Specialized Resource in the last nearly forty years has been providing various investigators carrying out Nuclear Medicine related research with positron emitting biomarkers. Until the ICMIC Program began, we supplied positron-emitting probes for studies primarily in large animals and in humans. With the development of microPET instrumentation, along with the influx of cell and molecular biologists who have turned to molecular imaging techniques under the ICMIC auspices, we now find our user base to have increased substantially, and the nature of the research we support to be far more varied. It has been both scientifically profitable and personally rewarding for the Cyclotron and Radiochemistry Specialized Resource staff to expand our interactions with the biological community at UCLA, as a result of the ICMIC extension of molecular imaging techniques throughout our molecular and cell biology community. The Cyclotron and Radiochemistry Specialized Resource is supported in part by income from clinical operations. Additional funds come from ICMIC resources and from individual grants that have Nuclear Medicine support components. Approximately 25% of our radiosynthesis work is for ICMIC programs; the bulk of the remainder of the research syntheses are for related basic sciences studies and for clinical programs. In reality, the clinical income supports and supplements, to some extent, programs that are under the ICMIC aegis.

专业资源1首席调查员/计划总监（最后，第一，中间）：Herschman，Harvey R. D.1。回旋和放射化学专业资源{董事N. Satyamurthy。博士学位） D.1.1。介绍。回旋和放射化学设施是UCLA-ICMIC和UCLA分子医学研究所（IMED）计划的专业资源组成部分。 Imed扎根于加州大学洛杉矶分校（UCLA）正电子发射断层扫描研究的长期以来的努力。因此，我们与IMED计划的历史早于NCI ICMIC的启动，该启动与原子能委员会以及后来的能源部有关，延伸了近四十年。 UCLA ICMIC的回旋和放射化学专业资源的主要目标是支持UCLA-ICMIC研究者的所有推广探针需求的研究和生产，即并为补充这些研究计划的其他UCLA研究项目提供服务。加州大学洛杉矶分校（UCLA）的回旋和放射化学专业资源于1971年7月开始运营。在1960年代，美国原子能委员会的生物学和医学部（AEC，能源部的前身AEC）培养了一项计划，旨在培养整个美国几个医疗中心的紧凑型环球子的安装和操作。目的是通过使大量具有理想的物理和化学特性的有前途的放射性核素可刺激放射性核素作为医学中的诊断工具的发展，但不能在核反应器中产生。结果，在UCLA启动了AEC赞助的医疗回旋计划，并由Cyclotron Corporation（CA Berkeley，CA）构建的CS-22型号Cyclotron，能够加速H*，d''，^He **和'He He^'^at at at at at at at at 1971年，在UCLA的一个专门建造的保险库中分别安装了22、12、31和24 MEV的固定能量。一家放射化学实验室和一家机械车间与Cyclotron一起，它们都位于UCLA医疗中心附近的单个故事建筑中，形成了原始的Cyclotron Core实验室。由于对放射性病的需求不断增长，在1990年，在CS-22 Cyclotron建筑物旁边的一座新建筑物中，新的11 MEV Proton RDS-112负离子回旋子（由CTI，KTI，KNOXVILLE制造）被添加到放射化学专业资源中。 1994年1月的北方北地震的后果要求替代CS-22回旋子。 1994年6月，仅11 MEV质子仅RDS-112负离子转基因（由CTI Knoxville制造）代替了受损的CS-22加速器。自1997年，自1997年进行了全面翻新，这是自设施成立以来的首次进行。新的紧凑型自固定的RDS-112回旋子仅占据了CS-22回旋子先前占据的拱顶的一半，使另一半可用于维护和修复与回旋体相关的组件。自1971年成立以来，该基因和放射化学专业资源具有支持UCLA核医学研究需求的悠久历史。借助CS-22回旋子，该专业资源已经开发了或采用了25多种不同放射性同位素的技术。作为集中式服务部门，在过去的四十年中，Cyclotron和放射化学专业资源已经为进行核医学相关研究的各种研究人员与正电子生物标志物相关研究。在ICMIC计划开始之前，我们为主要在大型动物和人类中的研究提供了推广探针。随着MicroPET仪器的发展，以及在ICMIC主持下转向分子成像技术的细胞和分子生物学家的涌入，我们现在发现我们的用户群可以大大增加，并且我们支持的研究性质会更加多样化。由于整个分子和细胞生物学界的分子成像技术的ICMIC扩展，这既是科学上的盈利，也是个人奖励，以扩大我们与UCLA生物群落的互动，以扩大我们与UCLA生物群落的互动。回旋和放射化学专业资源部分由临床收入支持运营。额外的资金来自ICMIC资源和具有核医学支持组成部分的个人补助金。我们的放射合成工作的大约25％用于ICMIC程序；其余研究合成的大部分用于相关的基础科学研究和临床计划。实际上，临床收入在某种程度上支持ICMIC AEGI下的计划。